Program
insulin icodec
Also written as “Insulin icodec”, “Insulin Icodec” and “IcoSema”.
Its studies are mostly in Diabetes Mellitus, Type 2 · Diabetes Mellitus, Type 1, led by Novo Nordisk.
Furthest: phase 4, since Aug 1, 202530 company-led studies, 2 open or runningNext primary completion: Jan 25, 2027 (phase 3)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Novo Nordisk | 302 open or running | phase 4since Aug 1, 2025 | Mar 8, 2013 | Jan 25, 2027phase 3 · NCT07076199 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 12 studies since Mar 8, 2013.
- Oct 8, 20203 phase 1 studies in Diabetes Mellitus, Type 2NCT04582448, NCT04582435, NCT04597697
- Feb 17, 20212 phase 3 studies in Diabetes Mellitus, Type 2NCT04760626, NCT04770532
- Mar 10, 2021Phase 3 study in Diabetes Mellitus, Type 2NCT04795531 · 588 enrolled · United States, Argentina, Austria and more
- Apr 16, 2021Phase 3 study in Diabetes Mellitus, Type 1NCT04848480 · 582 enrolled · United States, Austria, Canada and more
- Apr 22, 2021Phase 1 study in Diabetes Mellitus, Type 2NCT04857398 · 24 enrolled · China
- May 6, 2021Phase 3 study in Diabetes Mellitus, Type 2NCT04880850 · 582 enrolled · United States, Belgium, India and more
- Apr 24, 2022Phase 3 study in Diabetes Mellitus, Type 2NCT05352815 · 1,291 enrolled · United States, Australia, Belgium and more
- Jun 23, 2022Phase 1 study in Diabetes Mellitus, Type 2NCT05435677 · 20 enrolled · China
- Mar 17, 2023Phase 1 study in Diabetes Mellitus, Type 2NCT05790681 · 18 enrolled · United States
- Apr 3, 20232 phase 3 studies in Diabetes Mellitus, Type 2NCT05813912, NCT05823948
- Feb 23, 2024Phase 1 study in Diabetes Mellitus, Type 2NCT06288412 · 30 enrolled · Austria
- Mar 26, 2024Phase 3 study in Diabetes Mellitus, Type 2NCT06340854 · 412 enrolled · United States, Bulgaria, Germany and more
- Jul 14, 2025Phase 3 study in Diabetes Mellitus, Type 1NCT07076199 · 877 enrolled · United States, Australia, Canada and more
- Aug 1, 2025Phase 4 study in Diabetes Mellitus, Type 2NCT07112339 · 586 planned · Canada, Germany, Italy
Ahead
- Jan 25, 2027Primary completion: phase 3 study in Diabetes Mellitus, Type 1NCT07076199
- Mar 23, 2028Primary completion: phase 4 study in Diabetes Mellitus, Type 2NCT07112339
TargetBeta
INSR →read by rule
“Insulin receptor agonist”ChEMBL 37, by rule
Other programs on INSR
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Insulin Glarginerule | Sanofi | phase 4 | 190 |
| Insulin Aspartrule | Novo Nordisk | phase 4 | 146 |
| insulin degludecrule | Novo Nordisk | phase 4 | 108 |
| Insulinrule | Pfizer | phase 4 | 50 |
| insulin glulisinerule | Sanofi | phase 4 | 43 |
| linsitinibrule | Astellas Pharma | phase 3 | 13 |
| LY3938577 | Eli Lilly | phase 2 | 3 |
Studies
All 30 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07112339Diabetes Mellitus, Type 2 · Canada, Germany, Italy | 4 | Recruiting | Mar 23, 2028 | 586 |
| NCT07076199Diabetes Mellitus, Type 1 · United States, Australia, Canada and more | 3 | Active, not recruiting | Jan 25, 2027 | 877 |
| NCT06340854Diabetes Mellitus, Type 2 · United States, Bulgaria, Germany and more | 3 | Completed | May 8, 2025 | 412 |
| NCT06288412Diabetes Mellitus, Type 2 · Austria | 1 | Completed | Mar 10, 2025 | 30 |
| NCT05823948Diabetes Mellitus, Type 2 · United States | 3 | Completed | Mar 6, 2024 | 51 |
| NCT05813912Diabetes Mellitus, Type 2 · Czechia, Malaysia, Poland and more | 3 | Completed | Apr 14, 2025 | 148 |
| NCT05790681Diabetes Mellitus, Type 2 · United States | 1 | Completed | Feb 8, 2024 | 18 |
| NCT05435677Diabetes Mellitus, Type 2 · China | 1 | Completed | Apr 25, 2023 | 20 |
| NCT05352815Diabetes Mellitus, Type 2 · United States, Australia, Belgium and more | 3 | Completed | Mar 19, 2024 | 1,291 |
| NCT04880850Diabetes Mellitus, Type 2 · United States, Belgium, India and more | 3 | Completed | Jun 16, 2022 | 582 |
| NCT04857398Diabetes Mellitus, Type 2 · China | 1 | Completed | Apr 6, 2022 | 24 |
| NCT04848480Diabetes Mellitus, Type 1 · United States, Austria, Canada and more | 3 | Completed | Apr 28, 2022 | 582 |
| NCT04795531Diabetes Mellitus, Type 2 · United States, Argentina, Austria and more | 3 | Completed | Jun 23, 2022 | 588 |
| NCT04770532Diabetes Mellitus, Type 2 · United States, Bulgaria, Germany and more | 3 | Completed | Jan 27, 2022 | 526 |
| NCT04760626Diabetes Mellitus, Type 2 · United States, Bulgaria, Canada and more | 3 | Completed | Aug 12, 2022 | 1,085 |
| NCT04597697Diabetes Mellitus, Type 2 · Czechia, Slovakia | 1 | Completed | Mar 24, 2022 | 25 |
| NCT04582448Diabetes Mellitus, Type 2 · Germany | 1 | Completed | Sep 27, 2021 | 25 |
| NCT04582435Diabetes Mellitus, Type 2 · Austria | 1 | Completed | Apr 22, 2022 | 46 |
| NCT04460885Diabetes Mellitus, Type 2 · United States, Croatia, India and more | 3 | Completed | May 29, 2022 | 984 |
| NCT03951805Diabetes Mellitus, Type 2 · United States, Croatia, Germany and more | 2 | Completed | Dec 12, 2019 | 205 |
| NCT03945656Diabetes Mellitus, Type 2 · Austria | 1 | Completed | Sep 27, 2021 | 43 |
| NCT03922750Diabetes Mellitus, Type 2 · United States, Canada, Czechia and more | 2 | Completed | Dec 19, 2019 | 154 |
| NCT03789578Diabetes Mellitus, Type 2 · Germany | 1 | Completed | Oct 10, 2019 | 30 |
| NCT03766854Diabetes Mellitus, Type 1 · Japan | 1 | Completed | Dec 9, 2019 | 24 |
| NCT03751657Diabetes Mellitus, Type 2 · United States, Canada, Czechia and more | 2 | Completed | Dec 16, 2019 | 247 |
| NCT03723785Diabetes Mellitus, Type 2 · Germany | 1 | Completed | Sep 6, 2019 | 58 |
| NCT03723772Diabetes Mellitus, Type 1 · Germany | 1 | Completed | Jun 26, 2020 | 66 |
| NCT02964104Diabetes Mellitus · Germany | 1 | Completed | Dec 12, 2017 | 50 |
| NCT02148861Diabetes Mellitus · Germany | 1 | Completed | Jun 1, 2015 | 49 |
| NCT01809184Diabetes Mellitus · Germany | 1 | Completed | Sep 6, 2013 | 84 |
How it is read
Names in the registry
- “Insulin icodec”, 18 entries
- “insulin icodec”, 5 entries
- “Insulin Icodec”, 4 entries
- “IcoSema”, 1 entry
- “NNC0148-0287”, 1 entry
Conditions, from the studies’ own filings
- Diabetes Mellitus, Type 2, 26 studies
- Diabetes Mellitus, Type 1, 4 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.